Wall Street brokerages expect that Ziopharm Oncology Inc (NASDAQ:ZIOP) will report sales of $1.55 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Ziopharm Oncology’s earnings, with the lowest sales estimate coming in at $1.46 million and the highest estimate coming in at $1.60 million. Ziopharm Oncology posted sales of $1.60 million during the same quarter last year, which suggests a negative year-over-year growth rate of 3.1%. The company is expected to issue its next quarterly earnings report on Monday, May 7th.
On average, analysts expect that Ziopharm Oncology will report full-year sales of $1.55 million for the current fiscal year, with estimates ranging from $3.00 million to $6.40 million. For the next year, analysts forecast that the company will post sales of $6.39 million per share, with estimates ranging from $6.39 million to $6.40 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Ziopharm Oncology.
Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. The firm’s revenue was up .0% on a year-over-year basis.
Several research firms have weighed in on ZIOP. BidaskClub upgraded shares of Ziopharm Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. HC Wainwright set a $10.00 price target on shares of Ziopharm Oncology and gave the stock a “buy” rating in a research report on Thursday, December 14th. Raymond James Financial restated a “hold” rating on shares of Ziopharm Oncology in a research report on Monday, December 11th. Zacks Investment Research upgraded shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Saturday, January 6th. Finally, ValuEngine downgraded shares of Ziopharm Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.50.
ZIOP traded down $0.03 during trading on Monday, hitting $4.32. The company’s stock had a trading volume of 1,032,982 shares, compared to its average volume of 1,057,706. Ziopharm Oncology has a one year low of $3.33 and a one year high of $7.88. The company has a market capitalization of $619.43, a PE ratio of -8.15 and a beta of 1.72.
Several hedge funds have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Ziopharm Oncology by 127.5% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,896 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 14,513 shares during the period. Chevy Chase Trust Holdings Inc. bought a new stake in shares of Ziopharm Oncology during the 3rd quarter valued at $104,000. Geode Capital Management LLC raised its position in shares of Ziopharm Oncology by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company’s stock valued at $4,805,000 after purchasing an additional 22,575 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in shares of Ziopharm Oncology during the 3rd quarter valued at $145,000. Finally, Schwab Charles Investment Management Inc. grew its stake in Ziopharm Oncology by 4.2% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock valued at $2,669,000 after acquiring an additional 26,053 shares in the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/ziopharm-oncology-inc-ziop-expected-to-announce-quarterly-sales-of-1-55-million.html.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.